Articles Tagged With: VTE
-
Novel Combined Oral Contraceptives and VTE Risk: What Do We Know?
Recently, novel combined oral contraceptives containing estradiol valerate-dienogest, estetrol-drospirenone, and 17-beta estradiol with nomegestrol acetate have been released. Whether these types of estrogen are safer than ethinyl estradiol formulations in terms of venous thromboembolism risk is unknown.
-
LMWH vs. UFH in Pregnant Women Undergoing Anticoagulation
In this retrospective cohort study of pregnant women treated with low-molecular-weight heparin (LMWH) alone compared to those switched to unfractionated heparin (UFH) in the peripartum period, the outcomes were similar in both groups.
-
Etonogestrel Contraceptive Implant and VTE in Postpartum Women
In this national retrospective cohort study of postpartum women, use of the etonogestrel contraceptive implant immediately
postpartum was not associated with an increased rate of readmission for venous thromboembolism within 30 days of delivery. -
Venous Thromboembolism Risk After Abortion
Women experience a two-fold increase in risk of venous thrombosis (relative to nonpregnant women) following induced abortion, but a more than six-fold overall reduction in risk of thrombosis compared to women who continue the pregnancy to term.
-
Data Suggest Hormonal Therapy Doesn’t Increase VTE Risk in Women on Anticoagulant Therapy
Women on anticoagulant therapy can take estrogen-containing contraception or hormone therapy without an increased risk of blood clots or uterine bleeding, findings from a recent study suggest.